^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Imatinib...and second-generation TKIs (dasatinib...nilotinib...and bosutinib...) are all appropriate options for first-line TKI therapy for patients with CP-CML across all risk scores.
Evidence Level:
Sensitive: B - Late Trials
Title:

Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial

Published date:
04/13/2021
Excerpt:
In the phase 3 BFORE trial (Clinicaltrials.gov, NCT02130557), patients were randomized 1:1 to first-line bosutinib or imatinib 400 mg once daily….The major molecular response rate at 24 months favored bosutinib vs imatinib among Asian (63.6 vs 38.2%) and non-Asian (60.9 vs 52.6%) patients, as did the complete cytogenetic response rate by 24 months (86.7 vs 76.7%, 81.5 vs 76.3%).
DOI:
https://doi.org/10.1007/s12185-021-03144-4
Trial ID: